VMDHealthcare · Medical DevicesThe 2 Wall Street analysts covering Viemed Healthcare, Inc. hold a median 12-month price target of $13 — +32.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 8 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Viemed Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (91): The share price has been relatively steady.
Revisions (46): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +32.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Aug 2026 | Barrington Research | Initiates | Outperform | $14 |
| 6 Aug 2026 | Freedom Broker | Downgrade | Hold | — |
| 6 Aug 2026 | Freedom Broker | Downgrade | Hold | $11 |
| 3 Nov 2021 | RBC Capital | Maintains | Outperform | $13 → $9.00 |
| 3 Nov 2021 | RBC Capital | Maintains | Outperform | — |
| 5 Mar 2021 | RBC Capital | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VMD appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Viemed Healthcare, Inc. returned +37.0% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 29% of US stocks
Cheaper than 65% of US stocks
Cheaper than 37% of US stocks
Cheaper than 50% of US stocks
Higher than 73% of US stocks
Higher than 25% of US stocks
Higher than 71% of US stocks
Higher than 58% of US stocks
Higher than 59% of US stocks
Higher than 64% of US stocks
Higher than 88% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Viemed Healthcare, Inc. has a market value of $356.9M and an enterprise value of $358.2M.
Revenue in the twelve months to 30 June 2026: $301.6M. The latest quarter grew 23.9% year on year.
Net income over the same four quarters: $15.0M, a 5.0% net margin.
Diluted earnings per share, trailing twelve months: $0.36.
Free cash flow in the twelve months to 30 June 2026: $29.2M.
Viemed Healthcare, Inc. spent $20.5M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 25.8×; forward P/E: 23.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Viemed Healthcare, Inc. employs 1,438 people — $210K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Viemed Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights recent movements in the options market for Viemed Healthcare (VMD), saying investors should pay close attention to the stock.
Why it matters — VMD watchers may note the recent options-market activity, though the excerpt gives no details about its direction or significance.
Viemed Healthcare announced it will participate in the 20th Annual LD Micro Main Event, held October 19–21, 2026, in Los Angeles. The company is scheduled to present Tuesday, October 20, at 12:30 PM PT.
Why it matters — VMD watchers may note the scheduled investor-event presentation and its date and time.
Seeking Alpha reports that Viemed Healthcare is transitioning from a capital-intensive respiratory equipment company into a diversified, capital-light home healthcare provider. Expansion into sleep, resupply, and women's health segments is driving revenue growth while reducing capital intensity and supporting free cash flow acceleration, though the new business mix brings margin compression.
Why it matters — VMD watchers would care because the article highlights the company's improved capital efficiency and free cash flow profile, which it suggests requires only minimal annual growth to support current valuation.
Viemed Healthcare presented its growth strategy, product diversification, and capital allocation priorities at the Midwest IDEAS Conference. The company emphasized its focus on providing in-home care for patients with complex respiratory conditions and targeting low-20% growth as the home ventilation opportunity expands.
Why it matters — VMD watchers would gain insight into the company's strategic direction, growth outlook, and capital allocation plans as it positions itself in the expanding home ventilation market.
Seeking Alpha published the transcript of Viemed Healthcare, Inc.'s Q2 2026 earnings call. The transcript covers management's discussion and Q&A from the quarterly earnings presentation.
Why it matters — VMD watchers can read the full transcript of the company's Q2 2026 earnings call to review management commentary on the quarter's results.
The 2 Wall Street analysts covering Viemed Healthcare, Inc. have a median 12-month price target of $13, with estimates ranging from $11 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Viemed Healthcare, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viemed Healthcare, Inc. 94 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Viemed Healthcare, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (91 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +32.8% from the last close, and Ticker Nerd's factor model ranks Viemed Healthcare, Inc. 94 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Viemed Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $14 over the next 12 months.
Viemed Healthcare, Inc. returned +37.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Viemed Healthcare, Inc. is a healthcare company that provides home medical equipment and post-acute respiratory care services in the United States.
The most recent item we track (Zacks Investment Research, 7 Oct 2026): "Do Options Traders Know Something About Viemed Stock We Don't?". Zacks Investment Research highlights recent movements in the options market for Viemed Healthcare (VMD), saying investors should pay close attention to the stock.
Viemed Healthcare, Inc. is a healthcare company that provides home medical equipment and post-acute respiratory care services in the United States. The company focuses on in-home treatment for patients with respiratory conditions, offering equipment, therapy support, and clinical services designed to help manage complex breathing disorders outside traditional hospital settings. Its current product and service portfolio includes non-invasive ventilation, oxygen equipment, sleep apnea testing and treatment, positive airway pressure therapy, respiratory disease management, and related supplies and support services. Viemed also provides complementary clinical and staffing services that support patient care in the home. The company serves patients nationwide and operates within the broader home healthcare and durable medical equipment markets, where it plays a specialized role in respiratory-focused in-home care.
CEO Mr. Casey Hoyt · 1,438 employees · United States · https://www.viemed.com
